What was the overall market valuation of the US nuclear medicine market in 2024?

The overall market valuation was $1913.4 Million in 2024. Read More

What is the projected market valuation for the US nuclear medicine market by 2035?

The projected valuation for 2035 is $6244.4 Million. Read More

What is the expected CAGR for the US nuclear medicine market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 11.35%. Read More

Which application segment had the highest valuation in 2024?

The Diagnostic Imaging segment had the highest valuation at $2100.0 Million in 2024. Read More

What are the key players in the US nuclear medicine market?

Key players include GE Healthcare, Siemens Healthineers, Philips Healthcare, and Lantheus Medical Imaging. Read More

Which radioisotope type is projected to dominate the market by 2035?

Technetium-99m is projected to dominate the market, with a valuation of $2800.0 Million by 2035. Read More

What was the valuation of the Therapeutic Applications segment in 2024?

The Therapeutic Applications segment was valued at $500.0 Million in 2024. Read More

How much is the Radiopharmaceutical Production segment expected to grow by 2035?

The Radiopharmaceutical Production segment is expected to grow to $1400.0 Million by 2035. Read More

What is the projected valuation for hospitals as end users in 2035?

The projected valuation for hospitals as end users is $2675.56 Million by 2035. Read More

Which procedure segment had the lowest valuation in 2024?

The Brachytherapy procedure segment had the lowest valuation at $313.4 Million in 2024. Read More

US Nuclear Medicine Market

ID: MRFR/Pharma/15126-HCR

100 Pages

Satyendra Maurya

Last Updated: April 24, 2026

US Nuclear Medicine Market Research Report: Size, Share, Trend Analysis By Applications (Diagnostic Imaging, Therapeutic Applications, Radiopharmaceutical Production, Research Applications), By Radioisotope Type (Technetium-99m, Iodine-131, Fluorine-18, Yttrium-90), By End Users (Hospitals, Diagnostic Imaging Centers, Academic Research Institutions, Pharmaceutical Companies) and By Procedure (Positron Emission Tomography, Single-Photon Emission Computed Tomography, Radiotherapy, Brachytherapy) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Application (USD Million)
  1. 4.1.1 Diagnostic Imaging
  2. 4.1.2 Therapeutic Applications
  3. 4.1.3 Radiopharmaceutical Production
  4. 4.1.4 Research Applications
2. 4.2 Pharmaceutical, BY Radioisotope Type (USD Million)
  1. 4.2.1 Technetium-99m
  2. 4.2.2 Iodine-131
  3. 4.2.3 Fluorine-18
  4. 4.2.4 Yttrium-90
3. 4.3 Pharmaceutical, BY End User (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Diagnostic Imaging Centers
  3. 4.3.3 Academic Research Institutions
  4. 4.3.4 Pharmaceutical Companies
4. 4.4 Pharmaceutical, BY Procedure (USD Million)
  1. 4.4.1 Positron Emission Tomography
  2. 4.4.2 Single-Photon Emission Computed Tomography
  3. 4.4.3 Radiotherapy
  4. 4.4.4 Brachytherapy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GE Healthcare (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Siemens Healthineers (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Philips Healthcare (NL)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Canon Medical Systems (JP)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Elekta (SE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bayer AG (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bracco Imaging (IT)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Lantheus Medical Imaging (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 NorthStar Medical Radioisotopes (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY RADIOISOTOPE TYPE
4. 6.4 US MARKET ANALYSIS BY END USER
5. 6.5 US MARKET ANALYSIS BY PROCEDURE
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY RADIOISOTOPE TYPE, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY RADIOISOTOPE TYPE, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY PROCEDURE, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY PROCEDURE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY RADIOISOTOPE TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END USER, 2025-2035 (USD Million)
  4. 7.2.4 BY PROCEDURE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Application (USD Million, 2025-2035)

Diagnostic Imaging
Therapeutic Applications
Radiopharmaceutical Production
Research Applications

Pharmaceutical By Radioisotope Type (USD Million, 2025-2035)

Technetium-99m
Iodine-131
Fluorine-18
Yttrium-90

Pharmaceutical By End User (USD Million, 2025-2035)

Hospitals
Diagnostic Imaging Centers
Academic Research Institutions
Pharmaceutical Companies

Pharmaceutical By Procedure (USD Million, 2025-2035)

Positron Emission Tomography
Single-Photon Emission Computed Tomography
Radiotherapy
Brachytherapy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”